Eyestem raises $6.4M in Series A round

The investment will allow Eyestem to progress a treatment for Dry Age-related Macular Degeneration into clinical trials.

Eyestem, a Bengaluru-based cell therapy company, has raised $6.4 million (Rs 51 crore) in a Series A round led by three pharma majors: Biological E Limited (BE), Alkem, NATCO, and Kemwell Biopharma promoters Anurag and Karan Bagaria.

Endiya Partners and Kotak Private Equity, both existing investors, also participated in this round, valuing Eyestem at $46.4 million (Rs 371 crore) post-money.

"We started Eyestem with the sole purpose of being able to create cell therapy products at scale for diseases that devastate a large number of people in India and around the world," said Dr. Jogin Desai, Founder and CEO of Eyestem. The backing of major Indian pharmaceutical companies who share our vision validates our strategy of developing affordable innovation for patients all over the world. Following this funding, we will continue to focus on solidifying our cell therapy platform and advancing our flagship product for Dry AMD through international standard early clinical trials."

Eyecyte-RPE, the company’s patented flagship product, is an experimental treatment for Dry Age-related Macular Degeneration (Dry AMD) and the company has other products in the pipeline for the treatment of incurable diseases affecting humanity. EyeCyte-RPE replaces damaged retinal pigment epithelium cells and is designed to restore sight for patients in early stages of Macular Degeneration or arrest loss of vision for those in later stages. The product is allogenic, administered by a surgical procedure and is patented in India and abroad. The company intends to file for a first in human trial for the product within a year in consultation with CDSCO and US FDA. 

"We are very happy to be associated with Eyestem for its innovative work that services unmet needs of patients that have a high impact on quality of life," said Rajeev Nannapaneni, CEO of NATCO Pharma Limited.

"Endiya Partners is delighted to back such strong, globally competitive innovative startups and participate in the current funding round," said Dr Ramesh Byrapaneni, Managing Partner of Endiya Partners. The addition of leading pharma and biotech investors to our capitalization table is a great validation of the world-class science that Eyestem is pursuing, which has the potential to change millions of lives around the world."

Eyestem was founded in 2016 by an experienced team of clinical research, regenerative medicine, and ophthalmology experts. It is advised by a board of directors and has established collaborations with other leaders in related scientific disciplines in India, the United Kingdom, Japan, and the United States. Long-term goals include developing a scalable cell therapy platform to treat incurable diseases and democratizing global access to these newer technologies.

Tags : #Eyestem #funding #seriesaAround #fundingalert #DryAge-relatedMacularDegeneration #clinicaltrials #banglore #india #pharma #natco #medicircle #smiitakumar

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

FTCCI with support from the Ministry of MSME, Govt of Inia to host an International Conference on Shipping and Logistics at HICC on 22nd MarchMarch 18, 2024
Rotary donates Upgraded Neonatal ICU at Niloufer Hospital worth Rs 48 LakhsMarch 18, 2024
Fateh Education shares insight into Financial strategies and Post-Study employment goals of students aspiring to study abroadMarch 18, 2024
Empowering Communities: We Care Foundation Hosts 3rd Edition of I - Inspiration Awards, Championing Health, Finance, and Cyber WellnessMarch 18, 2024
Safeguarding Spectators: Medulance Partners with Zomato Live for On-site Medical Assistance at ZomalandMarch 18, 2024
Unsung hero, Chindu Yakshaganam theatre artist, Padma Shri Gaddam Sammaiah graced the 17th Annual Day of Anurag UniversityMarch 18, 2024
Multidisciplinary Approach at Citizens Specialty Hospital Saved 35-year-old Patient with Disc Prolapse following a recent Heart AttackMarch 18, 2024
Asia Pacific region’s First Patellofemoral Joint surgery is successful in India.March 18, 2024
FDA Greenlights Lupin's Varenicline Tablets: A Game-Changer in Smoking Cessation TherapyMarch 18, 2024
Deciphering STAP-1: A Promising Target for Immune-Related DiseasesMarch 18, 2024
The Gut-Brain Connection: How Gut Bacteria Shape Immunity and Prevent Allergic Reactions in NewbornsMarch 18, 2024
IIIT Hyderabad’s Annual R&D Showcase beginsMarch 16, 2024
Exploring New Horizons: The Role of Copper and Resveratrol in Cancer CareMarch 16, 2024
Expanding Healthcare Infrastructure: Delhi’s Ambitious EndeavourMarch 16, 2024
FTCCI's Tourism Committee brands cab drivers as ambassadors for tourism and trains 200 cab drivers at GMR Airport in Etiquette, Hygiene, First Aid, CPR and the English languageMarch 16, 2024
Musing of a Teenage Girl, a poetry book authored by a 14 years girl Sanjana Somavarapu releasedMarch 16, 2024
5th Edition FTCCI HR Awards 2023 Presented for best practices in people processesMarch 15, 2024
FTCCI Delegation visits T-WorksMarch 15, 2024
Debunking Myths: ICMR Study Disproves COVID Vaccine Link to Sudden DeathsMarch 15, 2024
Beware of Rhodamine-B: Several States in India Implement Ban on Artificial Food Coloring AgentsMarch 15, 2024